Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's (RRIPP-3)

July 2, 2018 updated by: Medical University of South Carolina
The goal of this study is to determine if supplementation with krill oil concentrate containing the phospholipid-bound omega-3 fatty acids improves performance on specific cognitive tests that underlie key elements in U.S. Army Infantry Basic Officer Leaders Course (IBOLC) and in Ranger School (Training) at Fort Benning, Georgia (GA).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The U.S. Army invests significant time and money in training its leaders. Individuals who choose the Army Infantry as their career expend significant time, energy, and commitment to self-development to achieve their career goals. While Infantry Basic Officer Leaders Course (IBOLC) graduates have demonstrated their ability to perform skills required for Ranger School success, personal stress during Ranger School appears to be a continual barrier to successful Ranger School graduation, with only 45.25% of IBOLC graduates having passed Ranger training in 2013. Omega-3 highly unsaturated fatty acids (HUFAs), specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are concentrated in neural tissues, are essential for neural function (McNamara & Carlson, 2006 ), and must be obtained from dietary sources. United States (U.S.) food production practices over the last century have resulted in a dramatic change in the fatty acid profile of the U.S. diet. At the same time, evidence continues to build regarding the potential importance of omega-3 HUFAs on emotional state, cognitive function, and mental health. The purpose of this study is to investigate whether supplementation with omega-3 HUFAs from a krill oil concentrate will improve emotional status and related cognitive performance under stress among Infantry Officer Trainees during IBOLC, (Part I) and subsequent Ranger School (Part II). More broadly, Americans continue to report living under a high level of stress, with 20% reporting states of severe stress. The potential impact of this study would be information that would support the role for dietary supplementation of omega-3 HUFAs from krill oil concentrate in contributing to improving mood, emotional status, and cognitive performance among the U.S. population.

Overview: The Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's (RRIPP-3 Study) is a double-blinded, randomized, placebo-controlled trial conducted by the Medical University of South Carolina (MUSC) in partnership with the National Institutes of Health (NIH) working with the permission of the leadership of IBOLC and the U.S. Army Ranger Training School at Fort Benning, GA. Participants (450 individuals) will be randomized to one of two experimental groups for 2 Parts: Part I: IBOLC and Part II Ranger School.

Intervention Schedule: Participants will be provided with capsules of krill oil concentrate (2.3g/day HUFAs with EPA and DHA ratio of approximately 2:1) or placebo (macadamia nut oil and appropriate matching colorant for krill oil) delivered in 8 capsules per day during Part I (IBOLC training) only.

Compliance Monitoring: Finger prick blood samples will be collected for assessment of fatty acids at baseline and at specific time points during IBOLC and pre- and post-Ranger training and analyzed at a collaborating laboratory at the National Institutes of Health.

Study Participants: Sample Size: The sample size calculation is based on differences in one of the specific cognitive tests between the placebo and treatment groups based on prior omega-3 supplementation studies. The total sample size needed to detect the between groups difference is 352 (176 per group). Accounting for a potential attrition rate of 25%, the total number of enrolled subjects=450. Calculations were made using PASS 2008 software, (Version 08.0.13, Kaysvile, Utah).

Location, Population, and Recruitment Strategy: This study will be conducted at Fort Benning, GA with laboratory analytic support at NIH and MUSC. All healthy individuals who have arrived at Fort Benning to participate in IBOLC with the intention of continuing directly into Ranger Training after completion of IBOLC will be eligible for the study. Information about the RRIPP-3 Study will be available to IBOLC students upon arrival at Fort Benning prior to IBOLC. Those interested in potentially participating in the study can review the information about the study at the beginning of IBOLC and sign up for a screening/enrollment session. After seeing videos about the study and the informed consent process, and answering eligibility questions, if students remain interested, they will be asked to sign an informed consent and Health Insurance Portability and Accountability Act (HIPAA) for the baseline assessments. Once consent is obtained, the volunteer will participate in study baseline and enrollment, randomized, and provided with their omega-3 HUFA or placebo capsules.

Study Sessions: Overview: All participants will be expected to participate in 5 sessions held at Fort Benning. During the enrollment session a 24-hour dietary recall and 30-day food frequency questionnaire will be administered. Subsequent sessions will be scheduled at the 8 week check-in and two mid-points of IBOLC, and after leaving Ranger School (whether training is completed or not). Trained study coordinators will collect the data for the RRIPP-3 study. With the exception of the dietary assessment interview, the assessments for the RRIPP-3 study will be participant self-responses. Whether by self-response or coordinator interview, the responses will be collected directly into an automated, assessment order-sequenced computer test battery. With the exception of the informed consent documents, all participant information will be directly entered into the MUSC secure server as part of the RRIPP-3 study file. Participants will be assigned a study ID number at enrollment that will be used for the study duration. All data will be collected and filed in conjunction with the participant study identification (ID) number.

United States Department of Agriculture (USDA) Automated Multiple-Pass Method (AMPM) 24-Hour Dietary Assessment: AMPM (USDA, http://www.ars.usda.gov/Services/ ) is a computerized method for collecting interviewer-administered 24-hour dietary recalls in person. Food Frequency Questionnaire: The Diet History Questionnaire (DHQ) is a freely available food frequency questionnaire (FFQ). The DHQ II consists of 134 food items and 8 dietary supplement questions. RRIPP-3 will use the DHQ II electronic version which includes usual intake over the previous 30 days with portion size (NCI, 2010).

Data Coding and Analysis: Data will be collected and managed using REDCap electronic data capture tools hosted at MUSC (redcap.musc.edu) (Harris et al., 2009). All coded RRIPP-3 study data will be collected and separately transferred to the MUSC secure server. This coded data will be labeled only with the participant study id and participant randomization number. Adverse events will be reported using eIRB, South Carolina's federated online IRB system.

Randomization Scheme: The 2 treatment groups will be balanced with respect to commissioning source and post-graduation destination using a stratified blocked design.

Statistical Analysis Intent to treat and verified compliance assessments: All hypotheses will be tested using both "intent to treat" and "as-per-protocol" criteria.

Data Analysis: Improvement on critical facets of cognitive function during IBOLC (Part I) and Ranger School (Part II): Descriptive statistics (e.g. means, standard deviations, medians, percentages) will be used to characterize the 2 treatment groups. T-tests, chi-square tests, or non-parametric tests (Wilcoxon rank sum, Fisher's exact) will be used to compare baseline characteristics between groups. As IBOLC class unit may represent an intraclass correlation, a variable will be created to represent class representation in the combined model. In addition, time on intervention and time to Part II end-point may vary between subjects and thus may be adjusted for in analysis as appropriate.

The primary analyses will involve generalized linear mixed models (GLMMs) (with random subject effects) performed to determine whether group assignment to active or placebo treatment improves scores on cognitive function and psychological assessments. The primary outcomes measure for cognitive function from the cognitive and psychological measures are outlined above. Other intermediary variables will be included in the model as indicated. Hypothesis tests will be 2-tailed, and p-values will be compared to an overall alpha level of 0.05. Secondary analyses will be conducted to examine treatment efficacy in subject subgroups, although the statistical power may be lower for any such analyses given the reduced sample size. GLMMs and non-linear mixed models with random subject and intraclass cluster effects will be used as appropriate.

Study Type

Interventional

Enrollment (Actual)

555

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Georgia
      • Fort Benning, Georgia, United States, 31905
        • US Army, Fort Benning
    • Maryland
      • Bethesda, Maryland, United States, 20892
        • National Institutes of Health
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Medical University of South Carolina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Entry into IBOLC
  2. No self-reported previous injuries that would impede potential physical performance success in IBOLC or Ranger training

Exclusion Criteria:

  1. Infection, autoimmune disease, or fever of unknown origin
  2. Coronary Heart Disease
  3. History of seizures, except for febrile seizures during childhood
  4. Known allergy to crustaceans (shellfish) or nuts
  5. Vegetarian food preference.
  6. Regular use of omega-3 containing supplements within the last 3 months.
  7. Reported consumption of seafood three or more times per week within the last three months.
  8. Carry diagnosis of Type I or Type II diabetes
  9. Take hypoglycemic agents
  10. Refusal to stop taking specific dietary supplements pertinent to the study with the exception of standard multivitamins during study participation
  11. For women, pregnancy or intention to become pregnant during the potential study duration

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Phospholipid-bound omega-3 supplement
2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
Dietary supplement: Phospholipid-bound omega-3 supplement
The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
PLACEBO_COMPARATOR: Placebo supplement
Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
Dietary supplement: Placebo supplement
Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change (vs. baseline) in Inhibition and Rule-Making
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Stroop
baseline, week 14, week 16, within 72 hours of ending Ranger training
Change (vs. baseline) in psychological resiliency
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Connor-Davidson Resilience Scale (CD-RISC)
baseline, week 14, week 16, within 72 hours of ending Ranger training
Group differences on Land Navigation scores (from IBOLC gradebook)
Time Frame: data collected by Army throughout 5 months of IBOLC training and scores summed at the end of 5 months and provided to study pi
Land navigation tests the ability of candidates to navigate from one point to another using a map and compass while equipped with their individual combat gear.
data collected by Army throughout 5 months of IBOLC training and scores summed at the end of 5 months and provided to study pi
Group differences on Marksmanship scores (from IBOLC gradebook)
Time Frame: data collected by Army throughout 5 months of IBOLC training and scores summed at the end of 5 months and provided to study pi
The underlying construct, visual psychomotor control, is assessed by evaluating whether "Marksman" or higher ranking was achieved on first attempt.
data collected by Army throughout 5 months of IBOLC training and scores summed at the end of 5 months and provided to study pi
Change (vs. baseline) in Focused Attention and Information processing speed
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Digit-Symbol Coding
baseline, week 14, week 16, within 72 hours of ending Ranger training
Change (vs. baseline) in physiological resiliency
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Composite score from Patient Reported Outcomes Measurement Information System (PROMIS), v. 1.0 for Applied Cognition, Fatigue, & Sleep-related impairment
baseline, week 14, week 16, within 72 hours of ending Ranger training

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change (vs. baseline) in Working Memory
Time Frame: baseline, week 14, week 16,within 72 hours of ending Ranger training
Figural Continuous Paired Associates Test (FCPAT; Turner, Drummond, Salamat, & Brown 2007)
baseline, week 14, week 16,within 72 hours of ending Ranger training
Anxiety as a Measure of Psychological Functioning
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Anxiety: Spielberger State / Trait Anxiety Inventory (STAI; Speilberger 1983)
baseline, week 14, week 16, within 72 hours of ending Ranger training
Stress Response
Time Frame: within 72 hours of ending Ranger training
Peritraumatic Distress Inventory (PDI; Brunet et al. 2001)
within 72 hours of ending Ranger training
Mood State as a measure of Psychological Functioning
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Mood State:Profile of Mood States - Bipolar (POMS-Bipolar;Lohr and McNair 1988)
baseline, week 14, week 16, within 72 hours of ending Ranger training
Change (vs. baseline) in Reasoning
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Grammatical Reasoning (Lieberman, Caruso, Niro, & Bathalon 2006)
baseline, week 14, week 16, within 72 hours of ending Ranger training
Change (vs. baseline) in Visual Attention
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Four-Choice Visual Reaction Time Test (Lieberman, Caruso, Niro, & Bathalon 2006)
baseline, week 14, week 16, within 72 hours of ending Ranger training
Change (vs. baseline) in Decision-Making
Time Frame: baseline, week 14, week 16, within 72 hours of ending Ranger training
Balloon Analogue Risk Task (BART: Lejuez et al., 2002)
baseline, week 14, week 16, within 72 hours of ending Ranger training

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of South Carolina

Collaborators

Aker Biomarine Antarctic AS

Investigators

  • Principal Investigator: Bernadette P Marriott, PhD, Medical University of South Carolina
  • Principal Investigator: Travis H Turner, PhD, Medical University of South Carolina

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 1, 2016

Primary Completion (ACTUAL)

June 1, 2018

Study Completion (ACTUAL)

June 1, 2018

Study Registration Dates

First Submitted

August 24, 2016

First Submitted That Met QC Criteria

September 16, 2016

First Posted (ESTIMATE)

September 21, 2016

Study Record Updates

Last Update Posted (ACTUAL)

July 5, 2018

Last Update Submitted That Met QC Criteria

July 2, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • Pro00051532

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fatty Acids, Omega-3

Clinical Trials on Phospholipid-bound omega-3 supplement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe